Clinical Trial Update: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase 1b/2 trial evaluating KRT-232 combined with ruxolitinib in myelofibrosis patients with suboptimal response to ruxolitinib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• KRT-232
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Kartos Therapeutics, Inc. | Conditions: Myelofibrosis | Phase 1, Phase 2 | Status: UNKNOWN